Clinical Trial: A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (Elowen-2)

U.S., Jan. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07355218) titled 'A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (Elowen-2)' on Jan. 12.

Brief Summary: The purpose of this global, multicenter, Phase 3 study is to evaluate the efficacy and safety of enpatoran over 24 weeks in participants with active cutaneous manifestations of lupus erythematosus with or without systemic disease. Study details include:

Study Duration: Up to 35 weeks. Treatment Duration: 24 weeks. Visit Frequency: every 4 weeks, with the exception of the Week 2 televisit. Study Intervention Name: Enpatoran, Placebo.

Intervention Form: Film-coated tablet.

Study Start D...